Skip to content
Study details
Enrolling now

Suvorexant Trial for AUD and PTSD

Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
NCT IDNCT06679062ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

76

Study length

about 12 months

Ages

21–65

Locations

2 sites in CA, TX

About this study

This trial is testing if suvorexant (SUV) can reduce insomnia in adults with post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD). Participants will receive either a placebo or SUV, followed by a two-week abstinence period from alcohol. They will track their symptoms using daily diaries and attend clinic visits to assess outcomes.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Placebo
  • 2.Take Suvorexant
PhasePhase 2
DrugSuvorexant
Routeoral
Primary goalChange in Insomnia Severity Index (ISI) score from baseline to Day 14

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low7%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

suvorexant

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Change in Insomnia Severity Index (ISI) score from baseline to Day 14.

Secondary: Change in PTSD total symptom severity score as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) from baseline to Day 14.

Body systems

Psychiatry / Mental Health